Difference between revisions of "Alcuronium chloride"

From Self-sufficiency
Jump to: navigation, search
m (1 revision)
Line 42: Line 42:
 
== References ==
 
== References ==
 
{{cite journal | author = Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K | title = Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. | journal = J Pharmacol Exp Ther | volume = 301 | issue = 2 | pages = 720–8 | year = 2002 | pmid = 11961078 | doi = 10.1124/jpet.301.2.720}}
 
{{cite journal | author = Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K | title = Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. | journal = J Pharmacol Exp Ther | volume = 301 | issue = 2 | pages = 720–8 | year = 2002 | pmid = 11961078 | doi = 10.1124/jpet.301.2.720}}
 +
 
{{cite journal | author = Maass A, Mohr K | title = Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors. | journal = Eur J Pharmacol | volume = 305 | issue = 1-3 | pages = 231–4 | year = 1996 | pmid = 8813558 | doi = 10.1016/0014-2999(96)00240-3}}
 
{{cite journal | author = Maass A, Mohr K | title = Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors. | journal = Eur J Pharmacol | volume = 305 | issue = 1-3 | pages = 231–4 | year = 1996 | pmid = 8813558 | doi = 10.1016/0014-2999(96)00240-3}}
{{cite journal | author = Jakubík J, Tucek S | title = Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium. | journal = J Neurochem | volume = 63 | issue = 5 | pages = 1932–40 | year = 1994 | pmid = 7931349}}
+
 
 +
{{cite journal | doi = 10.1046/j.1471-4159.1994.63051932.x | author = Jakubík J, Tucek S | title = Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium. | journal = J Neurochem | volume = 63 | issue = 5 | pages = 1932–40 | year = 1994 | pmid = 7931349}}
 +
 
 
{{cite journal | author = Proska J, Tucek S | title = Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. | journal = Mol Pharmacol | volume = 45 | issue = 4 | pages = 709–17 | year = 1994 | pmid = 8183250}}
 
{{cite journal | author = Proska J, Tucek S | title = Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. | journal = Mol Pharmacol | volume = 45 | issue = 4 | pages = 709–17 | year = 1994 | pmid = 8183250}}
  
Line 50: Line 53:
  
  
{{pharmacology-stub}}
 
  
 
[[Category:Muscle relaxants]]
 
[[Category:Muscle relaxants]]
 
[[Category:World Health Organization essential medicines]]
 
[[Category:World Health Organization essential medicines]]
 +
 +
 +
{{musculoskeletal-drug-stub}}
  
 
[[de:Alcuroniumchlorid]]
 
[[de:Alcuroniumchlorid]]

Revision as of 07:05, 11 September 2010

Alcuronium chloride
File:Alcuroniumchlorid.svg
File:Alcuronium3d.png
Systematic (IUPAC) name
4,4'-Didemethyl-4,4'-di-propenyltoxiferin-1-dichloride
Pharmacokinetic data
Metabolism not metabolized
Excretion 70-90% unchanged in urine 1.3ml/kg/min t1/2 2- 4 hours
Identifiers
CAS Number 23214-96-2
ATC code M03AA01 (WHO)
PubChem CID 5311001
IUPHAR/BPS 341
ChemSpider 20118193
Chemical data
Formula C44H50N4O2Script error: No such module "String".
Molar mass 666.894 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Alcuronium is a peripherally acting muscle relaxant in the curare alkaloid family. It is a semi-synthetic substance derived from toxiferine.

Effects

  • Cardiovascular system - histamine release and blockage of the sympathetic ganglia including adrenal medulla could cause Hypotension
  • Respiratory - apnea due to phrenic blockage but bronchoconstriction can occur from the histamine release
  • Central nervous system - no effect on intraoccular pressure
  • Autonomic ganglion blockade can cause decrease in gut motility

Special points

  • Duration of action prolonger in states of low potassium, calcium and protein, also in states of high magnesium and acidosis.
  • Pharmaceutically incompatible with thiopentone
  • Infusion can cause fixed dilated pupils

References

Zahn K, Eckstein N, Tränkle C, Sadée W, Mohr K (2002). "Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist". J Pharmacol Exp Ther. 301 (2): 720–8. doi:10.1124/jpet.301.2.720. PMID 11961078. 

Maass A, Mohr K (1996). "Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors". Eur J Pharmacol. 305 (1-3): 231–4. doi:10.1016/0014-2999(96)00240-3. PMID 8813558. 

Jakubík J, Tucek S (1994). "Protection by alcuronium of muscarinic receptors against chemical inactivation and location of the allosteric binding site for alcuronium". J Neurochem. 63 (5): 1932–40. doi:10.1046/j.1471-4159.1994.63051932.x. PMID 7931349. 

Proska J, Tucek S (1994). "Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors". Mol Pharmacol. 45 (4): 709–17. PMID 8183250. 


de:Alcuroniumchlorid

fr:Alcuronium ro:Alcuronium